当前位置:首页 >财报库 > 报告详情

吉利德科学Gilead Sciences(GILD)2024年负责任商业和影响报告「NASDAQ」(英文版)(83页).pdf

上传人: Kell****reet 编号:653856 2025-05-20 83页 20.44MB

下载:

1、2024 RESPONSIBLE BUSINESS AND IMPACT REPORT2024 R E S P O N S I B L E B U S I N E S S A N D I M PA C T R E P O R TImpactfor2024 RESPONSIBLE BUSINESS AND IMPACT REPORT2INNOVATE for ImpactABOUT THIS REPORT Gileads 2024 Responsible Business and Impact Report(formerly known as Gileads ESG Impact Report)

2、is an annual publication highlighting Gileads Corporate Responsibility activities,performance and data.It is intended to be reviewed in conjunction with Gileads stand-alone 2024 Responsible Business and Impact Report:Reporting Appendix,which contains additional information,data and alignment with ma

3、jor ESG reporting standards.The scope of this report includes all entities listed in Gileads 2024 Annual Report on Form 10-K and focuses primarily on our fiscal year ending Dec.31,2024.This report is intended to highlight some of the Companys responsible business efforts during the fiscal year ended

4、 Dec.31,2024;it is not a comprehensive description or representation of all of the Companys responsible business activities during that time.Unless otherwise noted,quantitative and qualitative data aligns with our fiscal year.Some qualitative information from both before and shortly after our fiscal

5、 year is also included.At the time of publication,quantitative environmental data covers our fiscal year ending Dec.31,2023,due to data collection and external assurance cycles.Fiscal year 2024 environmental data will be posted on G when it is available,typically in second quarter 2025.This report i

6、s intended for stakeholder use only and is not for promotional use.For information about Gilead products referenced in the report,please view the full Prescribing Information available on G.Please note that any investigational products or uses discussed within the report are not approved by the U.S.

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了Gilead公司2024年的企业责任与影响力报告。报告强调了Gilead在科学创新、全球健康、员工赋权等方面的成就。 1. Gilead在HIV领域取得了重大突破,研发出了一种名为lenacapavir的药物,用于HIV的预防。该药物在临床试验中显示了前所未有的疗效,有望成为HIV预防的重要工具。 2. Gilead通过自愿许可协议,与六家仿制药制造商签订了非独占、免版税的许可协议,使lenacapavir能在120个低收入国家迅速普及,如果获得批准。 3. Gilead在癌症治疗领域也取得了进展,其Trodelvy®(sacituzumab govitecan-hziy)药物在治疗转移性三阴性乳腺癌方面取得了显著的生存期数据。 4. Gilead还在炎症性疾病和病毒性疾病领域进行了创新,包括针对丙型肝炎和新型冠状病毒的药物研发。 5. Gilead致力于通过全球健康倡议、合作伙伴关系和慈善事业,使创新药物惠及全球最需要的人群。 6. Gilead在环境保护和社会责任方面也做出了努力,包括设定碳排放、水资源使用和产品包装的宏伟目标,以及推动员工包容性和发展。 综上所述,Gilead在科学创新、全球健康、环境保护和社会责任等方面都取得了显著的成就,致力于为全人类创造更健康的世界。
吉利德如何通过创新科学解决方案应对全球健康挑战? 吉利德如何通过自愿许可扩大全球对创新药物的获取? 吉利德如何通过社区合作和伙伴关系促进健康公平?
客服
商务合作
小程序
服务号
折叠